35例利妥昔单抗联合CHOP方案治疗B细胞非霍奇金淋巴瘤的疗效及其安全性

Efficacy of rituximab combined with CHOP chemotherapy for 35 patients with aggressive B cell non-Hodgkin's lymphoma

目的探讨利妥昔单抗联合CHOP方案治疗B细胞非霍奇金淋巴瘤的疗效以及其安全性。方法选取2011年2月~2014年5月辽宁医学院附属第三医学院血液科收治的70例B细胞非霍奇金淋巴瘤患者,并随机将其分为对照组和观察组,每组35例,对照组患者采取CHOP方案化疗,对照组在CHOP方案的基础上使用利妥昔单抗治疗,比较2组的疗效以及安全性。结果观察组有总有效率显著高于对照组（80.0%vs.37.1%;χ2=13.246,P〈0.001）。观察组与对照组出现发热反应的患者例数差异具有统计学意义（15vs.4;χ2=8.741,P=0.003）,出现白细胞减少以及胃肠道反应的患者例数差异不具有统计学意义,观察组出现发热反应的患者均在可承受范围内。结论利妥昔单抗联合CHOP方案联合治疗B细胞非霍金淋巴瘤的近期疗效较为理想,不良反应较少,有利于提高患者的生存质量。

Objective To analyze efficacy of rituximab combined with chemotherapy for 35 patients with aggressive B cell non-Hodgkin＇s lymphoma. Methods 70 patients with aggressive B cell non-Hodgkin＇s lymphoma were chosen from Hematology Department of First Affiliated Hospital of Liaoning Medical University and divided into observation group and control group at random,each group with 35 cases. The control group were treated with CHOP chemotherapy,and the observation group were treated with anti-CD20 monoclonal antibody rituximab combined with CHOP chemotherapy.The efficacy and toxicity of two group were compared. Results The total effective rate of observation group was significantly higher than that of control group（ 80. 0% vs. 37. 1%; χ2= 13. 246,P〈0. 001）. Fever cases of observation group were significantly more than those of control group（ 15 vs. 4; χ2=8. 741,P = 0. 003）,while the other adverse reactions of leucopenia and gastrointestinal reaction between two groups were not significantly different.Conclusion For patients with aggressive B cell non-Hodgkin＇s lymphoma,rituximab combined with CHOP chemotherapy has better short-term effects and its adverse reactions are tolerable,which helps patients to improve the quality of life.